Roles and regulatory mechanisms of miR-30b in cancer, cardiovascular disease, and metabolic disorders (Review)

MicroRNAs (miRNAs) are non-coding RNAs 21-23 nucleotides in length that regulate gene expression, and thereby modulate signaling pathways and protein synthesis in both physiological and pathogenic processes. miR-30b inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transfor...

Full description

Saved in:
Bibliographic Details
Published inExperimental and therapeutic medicine Vol. 21; no. 1; p. 44
Main Authors Zhang, Qing, Liu, Shousheng, Zhang, Jie, Ma, Xuefeng, Dong, Mengzhen, Sun, Baokai, Xin, Yongning
Format Journal Article
LanguageEnglish
Published Greece Spandidos Publications 01.01.2021
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Angiogenesis
Apoptosis
Autophagy
Biomarkers
Bladder cancer
Cancer
Cardiovascular diseases
Cell cycle
Cell growth
Colorectal cancer
Development and progression
Diagnosis
Drug dosages
Drug resistance
Gastric cancer
Gene expression
Genetic aspects
Growth factors
Health aspects
Kinases
Liver cancer
Lung cancer
Medical prognosis
Metabolic diseases
Metabolic disorders
Metastasis
MicroRNA
MicroRNAs
Mortality
Physiology
Review
Roles
Stem cells
Tumors
China
miRNA-30b
metabolism
cardiovascular diseases
biomarker
tumor
Online AccessGet full text

Cover

More Information
Summary:MicroRNAs (miRNAs) are non-coding RNAs 21-23 nucleotides in length that regulate gene expression, and thereby modulate signaling pathways and protein synthesis in both physiological and pathogenic processes. miR-30b inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transformation in multiple types of cancer. In addition to its role in several types of neoplasias, miR-30b has been shown to exhibit essential roles in cardiovascular and metabolic diseases. In the present review, an overview of the biological functions of miR-30b and its role in the pathogenesis of neoplastic, cardiovascular and metabolic diseases is provided. miR-30b is a potential candidate for clinical development as a diagnostic and prognostic biomarker, therapeutic agent and drug target. However, further research is required to elucidate its role in health and disease and to harness its potential clinical utility.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Abbreviations: AMI, acute myocardial ischemia; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; EGFR-TKIs, EGFR tyrosine kinase inhibitors; EMT, epithelial-mesenchymal transformation; miRNA, microRNAs; NAFLD, non-alcoholic fatty liver disease; NSCLC, non-small cell lung cancer; PAI-1, plasminogen activator inhibitor-1; RISC, RNA-induced silencing complex
Contributed equally
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2020.9475